Oligonucleotide Backbone Modifications
Sector: Education • Location: Switzerland
Source: EU Funding & Tenders Portal
Therapeutic oligonucleotides are rapidly emerging as novel modalities for the treatment of several previously unaddressable diseases. The development of oligonucleotide therapeutics has thereby been significantly driven by chemical modifications that enhance nuclease resistance, pharmacokinetic properties, and target engagement. Especially the modification of the phosphorus site at the internucleo
- Status
- Prospective
- Sector
- Education, Chemical (Industrial), Manufacturing (Industrial)
- Location
- Switzerland
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Oligonucleotide Backbone Modifications
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Therapeutic oligonucleotides are rapidly emerging as novel modalities for the treatment of several previously unaddressable diseases. The development of oligonucleotide therapeutics has thereby been significantly driven by chemical modifications that enhance nuclease resistance, pharmacokinetic properties, and target engagement. Especially the modification of the phosphorus site at the internucleoside linkage, in particular by the replacement of an oxygen with sulfur in the form of phosphorothioates, proved to be decisively beneficial. However, despite the immense and immediate impact, the current phosphorus backbone chemistry to form modified functionalities, such as phosphonates and phosphoramidates, remained severely limited by the classical reactivity at phosphorus. Expanding the chemical space of oligonucleotide backbone modifications requires transformations that can operate under mild conditions compatible with sensitive nucleic acid substrates. Here, we propose to explore the innovation potential of an unusually versatile method for oligonucleotide backbone modification developed in the framework of an ERC-CoG funded project. With the intellectual property protected by the filing of four patent applications, this Proof of Concept project aims to explore a stereoselective library creation by the divergent synthetic backbone modification platform. The method already allows linear and parallel synthesis from commercially available nucleosides via standard phosphoramidite synthesis and avoids the purification of sensitive intermediates. Efforts in this PoC will be focussed on diastereoselective oligonucleotide backbone modifications, the corresponding IP protection, licensing of the innovation as part of research collaborations with the pharmaceutical industry, and the creation of a spinout company. |
Location
Country | Switzerland |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Education, Chemical (Industrial), Manufacturing (Industrial) |
Article published date | 2026-09-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
